Resonance tests FerriScan
Tuesday, 01 July, 2008
WA-based diagnostics company Resonance Health (ASX: RHT) has lodged an application with the Australian Medical Services Advisory Committee seeking reimbursement for its FerriScan iron test in Australia.
The company has already had some public funding success overseas, with the Whittington Hospital in London receiving funding approval from the British National Health Service [NHS].
FerriScan is used in to test for and measure levels of iron overload in the liver, caused by regular blood transfusions received by patients with sickle cell disease, thalassemia major and myelodysplastic syndromes.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
